Esketamine (Spravato) was approved in 2019 for treatment resistant depression, but the medicine quickly gathered controversy about its long-term safety. We interview Dr. Nolan Williams from Stanford University about these issues and where esketamine fits in our interventions for treatment resistant depression.
Date Published: 1/13/2020
Duration: 12 minutes, 21 seconds
Take the Podcast Survey to help us launch a CME option in 2020.
No transcript available.
POWERED BY BLUBRRY
